Registry for children with congenital thymus missing
Part of Genetic & congenital, Immune system & allergy clinical trials.
This registry follows children born with congenital athymia (a missing or non-working thymus). It collects information around treatment with RETHYMIC, which may help researchers better understand how care and outcomes look over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) must be a pediatric patient diagnosed with congenital athymia.
- Your child is scheduled to start RETHYMIC within the next 30 days, or already received RETHYMIC within the last 60 days.
- Written consent must be provided.
- Consent can be given by the child (if able), or by a parent or legal guardian.
- If you cannot obtain written informed consent, you cannot join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study builds a family registry to better understand inherited transthyretin (hATTR) amyloidosis in adults with a confirmed genetic mutation. It may help researchers learn more about the condition and plan future studies, and it requires follow-up visits.
This study looks at how removing the thymus gland during infant heart surgery affects the immune system. It compares babies who have their thymus removed with those who have heart surgery without removing it, and with babies having other types of surgery.
This study creates a registry for people with thyroid hormone resistance caused by specific genetic mutations. It helps doctors collect data to better understand and treat the condition.
This is a research registry that enrolls people with achondroplasia or hypochondroplasia. It helps researchers collect information about the condition to improve understanding and future studies.
This early-phase study tests a cell treatment (Treg cells made from a child’s thymus tissue) to help prevent the body from rejecting a new heart. It may help reduce rejection risk, but it is experimental and involves added risks and follow-up.
This study is a registry that collects information about people diagnosed with rare histiocytic disorders. It helps doctors better understand these conditions over time and may improve future care.
Hear when a new Complete DiGeorge Anomaly trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.